MARKET

PRTA

PRTA

Prothena
NASDAQ
9.95
-0.03
-0.30%
Opening 12:32 05/29 EDT
OPEN
9.97
PREV CLOSE
9.98
HIGH
9.98
LOW
9.80
VOLUME
157.55K
TURNOVER
--
52 WEEK HIGH
11.80
52 WEEK LOW
4.320
MARKET CAP
520.91M
P/E (TTM)
-3.5389
1D
5D
1M
3M
1Y
5Y
1D
Major Prothena Investor Makes Bold New Move on the Stock
TipRanks · 2d ago
UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share
Benzinga · 2d ago
Prothena 10% owner William P. Scully buys 100,000 shares worth $981,300
PUBT · 2d ago
Weekly Report: what happened at PRTA last week (0518-0522)?
Weekly Report · 4d ago
Weekly Report: what happened at PRTA last week (0511-0515)?
Weekly Report · 05/18 10:07
Prothena Shareholders Reaffirm Board, Auditor and Pay Policies
TipRanks · 05/15 22:33
Prothena shareholders re-elect directors at annual meeting
PUBT · 05/15 20:39
Prothena files Form 3 initial beneficial ownership statement for William P. Scully
PUBT · 05/14 22:23
More
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.